83 related articles for article (PubMed ID: 14616352)
1. The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview.
Stockfleth E; Trefzer U; Garcia-Bartels C; Wegner T; Schmook T; Sterry W
Br J Dermatol; 2003 Nov; 149 Suppl 66():53-6. PubMed ID: 14616352
[TBL] [Abstract][Full Text] [Related]
2. UC-1V150, a potent TLR7 agonist capable of activating macrophages and potentiating mAb-mediated target cell deletion.
Dahal LN; Gadd A; Edwards AD; Cragg MS; Beers SA
Scand J Immunol; 2018 Jun; 87(6):e12666. PubMed ID: 29667229
[TBL] [Abstract][Full Text] [Related]
3. Management of patients with giant basal cell carcinoma during SARS COV2 outbreak in Italy.
Cantisani C; Rossi R; Nisticò SP; Vitiello M; Farnetani F; Bennaro L; Pellacani G
Transl Biophotonics; 2022 Aug; 4(3):e202200009. PubMed ID: 35942364
[TBL] [Abstract][Full Text] [Related]
4. TLR7 Agonist-Loaded Gadolinium Oxide Nanotubes Promote Anti-Tumor Immunity by Activation of Innate and Adaptive Immune Responses.
Wang X; Hirose M; Li X
Vaccines (Basel); 2024 Apr; 12(4):. PubMed ID: 38675755
[TBL] [Abstract][Full Text] [Related]
5. T-cell intrinsic Toll-like receptor signaling: implications for cancer immunotherapy and CAR T-cells.
Nouri Y; Weinkove R; Perret R
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34799397
[TBL] [Abstract][Full Text] [Related]
6. Ultraviolet Radiation and Basal Cell Carcinoma: An Environmental Perspective.
Teng Y; Yu Y; Li S; Huang Y; Xu D; Tao X; Fan Y
Front Public Health; 2021; 9():666528. PubMed ID: 34368047
[TBL] [Abstract][Full Text] [Related]
7. Toll-Like Receptors in Dermatology, Venereology, and Leprosy.
Gandhi S; Ravindra K
Indian J Dermatol; 2021; 66(2):223. PubMed ID: 34188292
[TBL] [Abstract][Full Text] [Related]
8. Sex and Gender Disparities in Melanoma.
Bellenghi M; Puglisi R; Pontecorvi G; De Feo A; Carè A; Mattia G
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32645881
[TBL] [Abstract][Full Text] [Related]
9. The road to new antiviral therapies.
Jerome KR
Clin Appl Immunol Rev; 2005; 5(1):65-76. PubMed ID: 32362789
[TBL] [Abstract][Full Text] [Related]
10. Targeting of Immune Cells by Dual TLR2/7 Ligands Suppresses Features of Allergic Th2 Immune Responses in Mice.
Laiño J; Wangorsch A; Blanco F; Wolfheimer S; Krause M; Flaczyk A; Möller TM; Tsai M; Galli S; Vieths S; Toda M; Scheurer S; Schülke S
J Immunol Res; 2017; 2017():7983217. PubMed ID: 29204451
[TBL] [Abstract][Full Text] [Related]
11. Bacterial flagellin-a potent immunomodulatory agent.
Hajam IA; Dar PA; Shahnawaz I; Jaume JC; Lee JH
Exp Mol Med; 2017 Sep; 49(9):e373. PubMed ID: 28860663
[TBL] [Abstract][Full Text] [Related]
12. Toll Like Receptor 2, 4, and 9 Signaling Promotes Autoregulative Tumor Cell Growth and VEGF/PDGF Expression in Human Pancreatic Cancer.
Grimmig T; Moench R; Kreckel J; Haack S; Rueckert F; Rehder R; Tripathi S; Ribas C; Chandraker A; Germer CT; Gasser M; Waaga-Gasser AM
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27941651
[TBL] [Abstract][Full Text] [Related]
13. Imiquimod-induced CCR9 Ameliorates murine TNBS Colitis.
Suzuki R; Katakura K; Fujiwara T; Gunji N; Watanabe H; Ohira H
Fukushima J Med Sci; 2016 Dec; 62(2):90-100. PubMed ID: 27829595
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral immunotherapy for melanoma.
Singh M; Overwijk WW
Cancer Immunol Immunother; 2015 Jul; 64(7):911-21. PubMed ID: 26050024
[TBL] [Abstract][Full Text] [Related]
15. An old friend with new skills: Imiquimod as novel inhibitor of Hedgehog signaling in basal cell carcinoma.
Gruber W; Frischauf AM; Aberger F
Oncoscience; 2014; 1(9):567-73. PubMed ID: 25594066
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of induced nitric oxide synthase enhances the anti-tumor effects on cancer immunotherapy using TLR7 agonist in mice.
Ito H; Ando T; Ogiso H; Arioka Y; Seishima M
Cancer Immunol Immunother; 2015 Apr; 64(4):429-36. PubMed ID: 25567751
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of indoleamine 2,3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model.
Ito H; Ando T; Arioka Y; Saito K; Seishima M
Immunology; 2015 Apr; 144(4):621-30. PubMed ID: 25322876
[TBL] [Abstract][Full Text] [Related]
18. Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation.
Singh M; Khong H; Dai Z; Huang XF; Wargo JA; Cooper ZA; Vasilakos JP; Hwu P; Overwijk WW
J Immunol; 2014 Nov; 193(9):4722-31. PubMed ID: 25252955
[TBL] [Abstract][Full Text] [Related]
19. The effect of imiquimod on matrix metalloproteinases and tissue inhibitors of metalloproteinases in malignant melanoma cell invasion.
Jung JY; Kim HS; Roh MR; Roh HJ; Lee SY; Chung KY
Ann Dermatol; 2014 Jun; 26(3):363-73. PubMed ID: 24966637
[TBL] [Abstract][Full Text] [Related]
20. Toll-like receptors and skin cancer.
Burns EM; Yusuf N
Front Immunol; 2014; 5():135. PubMed ID: 24744758
[No Abstract] [Full Text] [Related]
[Next] [New Search]
